Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 11:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-acetylcysteine or placebo Clear all
Completed Phase 2 Interventional Results available

A Study of N-Acetyl Cysteine in Children With Autism

NCT00627705
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine, Placebo - sugar pill
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132
View directory record Official record
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 1Phase 2 Interventional

N-acetylcysteine in Intra-amniotic Infection/Inflammation

NCT00397735
View directory record Official record
Conditions
Labor, Premature, Preterm Premature Rupture of the Membranes, Infection, Inflammation, Chorioamnionitis
Interventions
amniocentesis, N-acetylcysteine or placebo
Procedure · Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.

NCT04562597
View directory record Official record
Conditions
Surgery
Interventions
Dose Response Curve Placebo, Dose Response Curve N-acetylcysteine 50 mg/kg, Dose Response Curve N-acetylcysteine 100 mg/kg, Dose Response Curve N-acetylcysteine 150 mg/kg, Opioid Reduction with Optimal N-acetylcysteine Dose, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)

NCT00374088
View directory record Official record
Conditions
Transposition of Great Vessels, Congenital Heart Disease
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 3 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 9, 2026, 11:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Use of NAC in Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol

NCT03104959
View directory record Official record
Conditions
Prevention of Hangover Using N-Acety Cysteine
Interventions
N-acetyl cysteine, placebo
Dietary Supplement · Other
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 9, 2026, 11:17 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Antioxidant Use in Diabetes to Reduce Oxidative Stress

NCT03056014
View directory record Official record
Conditions
Ameliorating Oxidative Stress in Type 1 Diabetes
Interventions
N-acetyl cysteine, omega 6 Fish oil ( PUFA), Placebo
Drug · Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

NCT03480009
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone
Drug
Lead sponsor
Study Investigator-Sponsor
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

NCT02966873
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions
N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 11:17 PM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

NCT04880187
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
AXA1125, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 1 Interventional Results available

Hypertrophic Regression With N-Acetylcysteine in HCM

NCT01537926
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine for Tobacco Use Disorder

NCT02737358
View directory record Official record
Conditions
Nicotine Dependence, Smoking
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 4 Interventional

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCT02505477
View directory record Official record
Conditions
Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
Interventions
N-acetylcysteine, Treatment as Usual
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 9, 2026, 11:17 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

NCT01797575
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aspirin, N-acetyl-cysteine (NAC), Sugar Pill
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

NCT00453180
View directory record Official record
Conditions
Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 12 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Glutathione and Fuel Oxidation in Aging

NCT01870193
View directory record Official record
Conditions
Aging
Interventions
Glycine, cysteine (as n-acetylcysteine), alanine
Dietary Supplement
Lead sponsor
Rajagopal V Sekhar
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

NCT01537081
View directory record Official record
Conditions
Acute Upper Respiratory Tract Infection
Interventions
Mucinex, Immediate-release Guaifenesin, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
12 Years and older
Enrollment
2,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Hoover, Alabama • Bell Gardens, California • Harbor City, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 9, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder

NCT03008889
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
5 Years to 12 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 9, 2026, 11:17 PM EDT